According to REISAMIC (a French, multicenter, prospective registry), the relative incidence of tuberculosis (TB) was approximately one in 1000 among cancer patients receiving PD1/PD‐L1 inhibitors.20 Furthermore, in 2018, Japan reported a case of exacerbation of chronic progressive pulmonary aspergillosis (CPPA) in a patient receiving 20 courses of nivolumab.21 The same year, another patient treated with nivolumab was reported to have developed varicella zoster virus (VZV) infection during treatment.22 None of the aforementioned cases had irAEs or immunosuppressive therapy. Here, CD274 is linked to tuberculosis.